Jacobs Levy Equity Management
ARQT icon

Jacobs Levy Equity Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Jacobs Levy Equity Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100,172
Closed -$932K – 938
2024
Q3 		$932K Sell
100,172
-75,737
-43% -$747K ﹤0.01% 732
2024
Q2 		$1.64M Buy
+175,909
New +$1.59M 0.01% 640
2023
Q1 		– Sell
-190,818
Closed -$2.82M – 957
2022
Q4 		$2.82M Sell
190,818
-41,395
-18% -$723K 0.02% 490
2022
Q3 		$4.44M Buy
+232,213
New +$5.26M 0.04% 418

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Jacobs Levy Equity Management's ARQT Position: Q4 2024 in Review

Jacobs Levy Equity Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 100,172 shares — an estimated $932K sold.

Jacobs Levy Equity Management first reported a position in ARQT in Q3 2022 and held it in 4 quarters. The position peaked at $4.44M in Q3 2022. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • Jacobs Levy Equity Management reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 100,172 Arcutis Biotherapeutics shares in Q4 2024, an estimated $932K.
  • Jacobs Levy Equity Management first reported a position in Arcutis Biotherapeutics in Q3 2022 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Arcutis Biotherapeutics position peaked at $4.44M in Q3 2022.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2024, filed 14 Feb 2025.